1. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Issue 10379 (11th March 2023) Authors: Keech, Cheryl; Miller, Vicki E; Rizzardi, Barbara; Hoyle, Christopher; Pryor, Melinda J; Ferrand, Jonathan; Solovay, Ken; Thalen, Marcel; Noviello, Stephanie; Goldstein, Peter; Gorringe, Andrew; Cavell, Breeze; He, Qiushui; Barkoff, Alex-Mikael; Rubin, Keith; Locht, Camille Journal: Lancet Issue: Volume 401:Issue 10379(2023) Page Start: 843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗